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The first-generation tests targeting a cryptic plasmid for the C. trachomatis diagnostics showed 
a relatively high sensitivity; however their usefulness has recently been compromised by the 
discovery of C. trachomatis strains lacking the target DNA segment (e.g. the “Swedish” 
variant) or variants bearing no plasmid at all and thus escaping the diagnostics. Aim. We 
propose the addition of a C. trachomatis chromosome gene as a PCR target to back up plasmid-
based assays and enhance the overall efficiency of diagnostics. Methods. Two multiplexed 
PCRs were set up to target C. trachomatis cryptic plasmid and the 16s rRNA gene. The 16s 
rRNA primers produce PCR signal from a range of Chlamydia species whereas the introduc-
tion of a Taqman probe (essential for the real-time PCR) scales the assay down to C. trachoma-
tis. At the same time, our plasmid PCR is specific to C. trachomatis exclusively. Results. The 
sensitivity of plasmid and 16s rRNA PCRs ranged between one to ten genome-equivalents per 
reaction (geq/rxn) whereas the efficiency was always ~100%. Multiplexing did not reduce the 
analytical sensitivity. Addition of DNA prepared from clinical specimens to the reaction mix 
did not affect PCR with pure C. trachomatis DNA further demonstrating the robustness of this 
system. The kinetics of the two reactions was compared in 49 DNA samples prepared from 
C. trachomatis-positive swabs. In 45, reactions showed a good correlation in the threshold 
cycle of amplification Cq, the main analytical parameter of real-time PCR. Conclusions. The 
simultaneous detection of chromosomal and plasmid targets in the multiplex PCR offers a high 
sensitivity and is particularly advantageous for specimens where the plasmid might be lost due 
to DNA degradation or counter-selection after treatment. The dual PCR strategy constitute the 
core of a diagnostic test for both in-house and commercial use.
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Introduction
Chlamydia is a causative agent of a series 
of urogenital, respiratory and ocular disor-
ders in humans and animals [1]. Although in 
most cases infections are asymptomatic, se-
vere outcomes occur when the pathogen-
associated damage is aggravated by an in-
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adequate immune response [2, 3]. C. tracho-
matis is the most clinically important and 
hence best-stu died representative of the 
phylum. This is a sexually transmitted obli-
gate intracellular gram-negative bacterium. 
If not treated it can cause pelvic inflamma-
tory disease, infertility, ectopic pregnancy, 
urethritis, infant pneumonia and blind-
ness [3]. Therapy of C.trachomatis infection 
relies mainly on broad-spectrum antibiotics 
such as azithromycin and doxycycline, and 
no pathogen-specific treatment has been 
implemented as yet [4]. 
The diagnostics of Chlamydia infection in 
humans and animals makes a wide use of 
PCR [4]. For C. trachomatis, the cryptic plas-
mid which is somehow linked with infectivi-
ty [5] has long been the primary target in PCR 
tests [6]. The plasmid is present in up to 10 
copies per cell [7]. However, a variant was 
discovered in Sweden where the plasmid had 
a deletion encompassing the target region used 
in diagnostic kits of that time [8, 9]. It was 
suggested that the deletion had been rapidly 
selected due to the diagnostic advantage it 
provided to the microorganism oppressed by 
screening programs. Moreover, plasmid-less 
variants have also been reported [10, 11]. 
Therefore, other PCR targets have been sug-
gested: momp1 (major outer membrane pro-
tein) [12], omcB (outer membrane complex 
B protein) [13], gyrase A [14], 16s rRNA [10, 
15], 23s rRNA 
Here we present a set of PCRs targeting the 
C. trachomatis cryptic plasmid, 16s rRNA 
gene and a synthetic plasmid as an internal 
control. These reactions could constitute the 
basis of an in-house or affordable commercial 
diagnostic kit. They are highly sensitive, robust 
and amenable for multiplexing. The dual-target 
strategy appears to be particularly useful for 
problematic specimens in which a partial loss 
of DNA due to degradation or deletion might 
be an issue.
Methods
Samples
Chlamydia reference DNA samples were ob-
tained as a gift from the German Reference 
Center for Chlamydial Infections at the Insti-
tu te of Microbiology, Friedrich-Schiller-Uni-
ver sity Jena (Jena, Germany); Bacillus cereus 
DNA was a gift from Dr. Tigran Yuzbashev 
(Institute for Genetics and Selection of 
Industrial Microorganisms, Moscow, Russia). 
Lactobacillus rhamnosus DNA was isolated 
from a culture purchased at Probiotical SpA 
(Novara, Italy). Escherichia coli, Bacillus ce-
reus, Listeria monocytogenes, Mycoplasma 
arginini, Campylobacter pylori DNA was iso-
lated from stocks deposited at the State 
Scientific Control Institute of Biotechnology 
and Strains of Microorganisms (Kyiv, Ukraine). 
DNA isolation was done using GeneJET 
Genomic DNA Purification Kit (Thermo Fisher 
Scientific, Waltham, MA, USA). Clinical spec-
imens (vaginal, endocervical and urethral 
swabs) were kindly provided by several com-
mercial and hospital labs in Kyiv, Ukraine. 
Patients ordering a C. trachomatis PCR test 
have signed consent for research use of their 
specimens. The Ethic Committee of the State 
Scientific Control Institute of Biotechnology 
and Strains of Microorganisms approved the 
use of human clinical specimens in this re-
search. All biological materials were properly 
destroyed. 
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Internal control
A pUC18 — based plasmid bearing Thermus 
thermophilus tRNATyr gene as a SmaI – BamHI 
insert was kindly provided by Prof. Mykhailo 
Tukalo (Institute of Molecular Biology and 
Genetics, Kyiv, Ukraine). 
PCR
PCR was performed with oligonucleotides 
(Table 1) designed with the aid of the Vector 
NTI® software (Thermo Fisher Scientific, 
Waltham, MA, USA) and primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-
blast). The reaction volume was 25 µl. The oli-
go nucleotide quantity per reaction was as given 
in Table (right column). Other components were: 
1x DreamTaq PCR buffer, 0.1 mM dNTP, 3 mM 
MgCl2, 0.6 mg/ml bovine serum albumin, 4 % 
glycerol, DreamTaq polymerase (Thermo Fisher 
Scientific, Waltham, MA, USA) or TaqF poly-
merase (Interlabservice, Moscow, Russia). PCR 
program was: pre-denaturation, 95 °C for 
10 min; amplification for 40–45 cycles of: 95 °C 
for 10 sec, 62 °C for 20 sec, 72 °C for 30 sec. 
Typically, 5 ul sample DNA were added to PCR. 
Real-time PCR was done on a Biorad CFX-96 
PCR system (Biorad, Hercules, CA, USA). 
The threshold cycle of amplification Cq was 
registered as a point at which the amplification 
curve reached the intensity of fluorescence of 
50 relative units. The efficiency of PCR was 
calculated using the formula:
E = 10–1/slope – 1
where E — efficiency, “slope” — the slope of 
the trend line of the Cq dependence on the 
log10 of concentration of reference C. tracho-
matis DNA (Fig. 3B and C).
Results 
Primers, probes and target regions
Our principle idea was to supplement a plasmid-
based reaction with another one targeting some 
genomic fragment. Thus the test would be in-
sured from plasmid-instability issues while 
keeping an elevated level of the analytical sen-
sitivity suggestively provided by several copies 
of plasmid. The 16s rRNA gene was chosen as 
the target genomic fragment due to a unique 
pattern of conservative and hypervariable mo-
tives [15]. There are two copies of this gene in 
C. trachomatis separated by about 20 kb 
(Fig. 1A). Primers were designed to detect a 
range of Chlamydia species thus reserving a 
possibility of detecting the Chlamydia genus 
without specification which might be in demand 
in certain clinical and veterinary situations. 
At the same time, the hexachlorofluorescein 
(HEX)-labeled Taqman probe is C. trachoma-
tis — specific: mismatches to the corresponding 
sequence of other species are sufficient to ab-
rogate the detection in real-time PCR (Fig. 1A). 
The cryptic plasmid is detected by a pair of 
primers targeting the predicted coding se-
quence CDS3 (Fig. 1B). Note that the targeted 
region lies outside of the 377-bp Swedish de-
letion. The function of CDS3 is yet unknown; 
interaction with other plasmid-born CDSs and 
chromosomal genes has been suggested [16]. 
The probe is labeled by 6-carboxyfluorescein 
(FAM) thus enabling multiplexing with the 16s 
rRNA PCR detected by HEX fluorescence. 
If PCR reaction is aimed to be used as a 
diagnostic test it must be accompanied by an 
internal control reaction. A positive PCR signal 
from the internal control would indicate that 
PCR conditions were correct and the compo-
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Fig. 1. PCR targets for C. trachomatis detection. A – The 
16s rRNA gene on C. trachomatis 434/Bu chromosome 
(GeneBank NC_010287.1). One of the two 16s rRNA 
loci is zoomed to show the region targeted by primers 
(green arrowheads) and probe (red block). Rulers above 
the maps show the chromosomal coordinate in kilobase 
pairs. The probe sequence is given in bold. The corre-
sponding sequences of Chlamydia species are shown 
with mismatches highlighted by red letters. B – C. tra-
chomatis cryptic plasmids. Plasmid with rearrangements 
characteristic of the Swedish variant is shown by the in-
ner circle, wild-type by the outer. Positions of primers are 
shown by arrows. This panel is adopted from a diagram 
published earlier [9]. A kind permission of the author, 
Dr. Helena Seth-Smith, was granted.
A
B
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nents of the PCR machinery worked properly. 
In this case, a negative result of the target reac-
tion could surely be interpreted as the absence 
of the pathogen DNA in the sample (or its 
presence below the sensitivity threshold), not 
as a result of PCR failure. We designed a third 
reaction templated by the pUC18 plasmid bear-
ing an insert in the multiple cloning site (see 
Materials and Methods). This plasmid should 
be added to the reaction mix along with sam-
ple DNA. The forward primer anneals to the 
insert; the reverse primer anneals to the b-
Lactamase gene which is a part of the original 
pUC18 backbone sequence. It was crucial to 
position one of the primers to a synthetically 
introduced insert. If we otherwise placed both 
primers to the backbone an undesirable back-
ground PCR signal would be produced from 
the homologous expression vectors usually 
present in recombinant Taq polymerase stocks 
as an admixture. Note that such vectors are 
inevitably carried over to the PCR mix and 
produce a detectable amplicon [17] after about 
30 cycles (data not shown). The Taqman probe 
for this reaction carries the cyanine 5 (Cy5) 
dye whose maximum of fluorescence emission 
(670 nm) lies away from that of FAM (517 nm) 
and HEX (556 nm) labeling the 16s rRNA and 
cryptic plasmid reactions, respectively. PCR 
with 16s rRNA primers amplified a distinct 
156-bp product from purified DNA of C. tra-
chomatis (Fig. 2, lanes 2 and 3) and some 
other Chlamydia species (Fig. 2, lanes 8–14). 
No 156-bp product was detected in DNA from 
Escherichia coli, Bacillus cereus, Listeria 
monocytogenes, Mycoplasma arginini (Fig. 2, 
lanes 4–7), Bacillus thermocatenulatus, 
Campylobacter pylori, Lactobacillus rhamno-
sus (data not shown). Non-specific products of 
a higher molecular weight seen in PCR from 
some non-Chlamydia species have no diagnos-
tic value. Cryptic plasmid, appearing as a 
266-bp product, was detected only in PCR 
from C. trachomatis DNA (Fig. 2, lane 3). 
PCR from reference C. trachomatis DNA
A triplex PCR consisting of reactions targeting 
the 16s rRNA gene and cryptic plasmid of 
reference C. trachomatis along with internal 
control produced a typical sigmoid curve 
(Fig. 3A) and distinct electrophoretic band 
(Fig. 3B) for each of the three reactions. Note 
that the internal control PCR (smooth grey 
curves) does not appear to be inhibited by the 
two diagnostic reactions (symbol-marked 
curves) even at elevated concentrations of tem-
plate DNA. The individual analytical sensitiv-
ity of the diagnostic reactions in triplex was 
assayed on ten-fold dilutions of pure C. tracho-
matis DNA spanning four orders of magnitude 
(Fig. 3C and D). Reproducible sigmoid curves 
were observed for both reactions in the pres-
ence of as low as five genome-equivalents per 
Fig. 2. PCR from the 16s rRNA gene and cryptic plasmid 
on reference strains. Amplicons generated with primers to 
16s rRNA (2–14) and plasmid (3–14). 1 – Molecular 
weight marker producing the bands whose sizes are shown 
in base pairs (bp). 2,3 – Chlamydia trachomatis, 4 – Esche-
richia coli, 5 – Bacillus cereus, 6 – Listeria monocyto-
genes, 7 – Mycoplasma arginini, 8 – Chlamydia suis, 9 – 
C. mudidatum, 10 – C. abortus, 11 – C. felis, 12 – C. psit-
taci, 13 – C. avium, 14 – C. pecorum 
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A
C
D
B
Fig. 3. Sensitivity and efficiency of multiplex PCR for C. trachomatis. A – Triplex real-time PCR with primers to 16s 
rRNA (green triangles), cryptic plasmid (blue circles) and internal control (grey). C. trachomatis DNA was added in 
the amount indicated as log10 geq/rxn. The internal control was added as well. B – PCR from C.trachomatis DNA 
without (lane 2) or with (lane 3) the addition of internal control plasmid. Molecular weight marker (lane 1) produces 
bands whose sizes are shown in base pairs (bp). C – Of three reactions, only the one targeting cryptic plasmid is 
shown. The PCR efficiency was deduced from the plot of Cq to log geq/rxn given at the right (mean of three reactions, 
error bar: standard deviation). D – same as (c) but for 16s rRNA PCR.
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reaction mix (which is equal to the value of 0.7 
in the logarithmic form). We monitored Cq, 
a PCR cycle at which the kinetics passes from 
the lag to exponential stage. The Cq is consid-
ered as the main quantitative parameter of real-
time PCR. In our assays, a ten-fold increment 
in the template concentration translated in the 
Cq decrease of about 3.3 cycles throughout the 
entire concentration range. Consequently, the 
PCR efficiency was close to one (100 %) indi-
cating that (i) no loss of sensitivity happens 
upon dilution of the sample, (ii) no inhibition 
is caused by higher concentrations of tem-
plate DNA. 
It is often speculated that multiplexing 
might weaken PCR because of unpredictable 
oligonucleotide heteroduplexes and/or ex-
hausting PCR components. We compared the 
performance of our diagnostic reactions in the 
monoplex versus triplex format (Fig. 4, smooth 
and symbol-marked curves, respectively). 
No significant change in Cq and overall shape 
of curves has been observed at both high 
(4.7 log10 geq/rxn) and low (0.7 log10 geq/rxn) 
concentrations of pure C. trachomatis DNA. 
Thus we could dispel concern of a sensitivity 
loss due to multiplexing.
Clinical samples
Up to this point, the proposed strategy of dual-
target PCR has been tested only on pure refer-
ence DNA. Skepticism might hold that DNA 
from real clinical specimens could perform 
weaker in terms of the sensitivity and robust-
ness. In view of this, we examined our reac-
tions in triplex on reference C. trachomatis 
DNA with and without DNA isolated from 
C. trachomatis-negative specimens (Fig. 5, 
symbol-marked and smooth curve, respec-
tively). Plasmid and 16s rRNA PCRs (Fig. 5A 
and B, respectively) produced a detectable 
fluorescent signal throughout a range of tem-
plate DNA concentrations spanning four orders 
of magnitude. We did not observe any signifi-
cant difference between real-time PCR curves 
registered in the presence or absence of clini-
cal sample DNA. Thus the proposed PCR reac-
tions are robust enough for the detection of 
C. trachomatis DNA in clinical specimens.
Next we compared the performance of 16s 
rRNA and cryptic plasmid reactions on real 
C. trachomatis — positive samples (deemed 
such by commercial PCR kits; Fig. 6). We 
carried out triplex PCR (with the addition of 
internal control) and plotted the results as dots 
on the plane formed by two Cq values. In such 
representation, the results lie along the diago-
nal line indicating that the two reactions sense 
the variation of the amount of C. trachomatis 
DNA in a similar manner. There were 45 such 
Fig. 4. A negligible effect of multiplexing on the PCRs 
for C. trachomatis. Pure C. trachomatis DNA was used 
to give the indicated number of log 10 geq/rxn. PCR was 
done either in triplex with primers to 16s rRNA (green 
triangles) + cryptic plasmid (blue circles) + internal con-
trol (not shown) or monoplex with primers to 16s rRNA 
 or cryptic plasmid (green and blue curves, respectively, 
without any symbol). 
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samples out of total 49. In four outliers, one 
of the two reactions failed or poorly performed 
as judged by a higher Cq: one with plasmid 
and three with 16s rRNA. These results were 
essentially confirmed by re-analyzing the back-
up stocks starting from DNA (data not shown). 
Overall, the two reactions were equally effi-
cient on clinical specimens: the mean Cq was 
28.2 and 28.3 for cryptic plasmid and 16s 
rRNA, respectively. Therefore, 16s rRNA and 
cryptic plasmid PCRs can complement each 
other in problematic cases thereby minimizing 
the chance of a false-negative result.
Discussion
About 90 million cases of C. trachomatis infec-
tion are diagnosed worldwide and the incidence 
has grown within the last decade [18]. A large 
proportion of infections proceeds asymptho-
matic and undetected, yet pelvic inflammatory 
disease could develop with a various probabil-
ity and cause infertility in up to 18 % of cases 
[19]. Despite screening programs have been 
designed and promoted recently [20], many 
communities and regions still have a limited 
access to high-quality C. trachomatis diagnos-
tics. The advent of molecular techniques, such 
A
B
      
Fig. 5. A negligible effect of DNA 
prepared from a clinical specimen on 
the PCRs for C. trachomatis. Pure 
C. trachomatis DNA was used to 
give the indicated number of log10 
geq/rxn. PCR was done in triplex 
with primers to 16s rRNA + cryptic 
plasmid + internal control. Of the 
three reactions, only cryptic plasmid 
(A) or 16s rRNA (B) PCRs are 
shown. Curves registered in the pres-
ence of DNA from a C. trachoma-
tis – negative clinical sample are la-
belled with triangles or circles.
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Fig. 6. Scatter of Cq values of PCR from clinical sam-
ples. Forty nine clinical C. trachomatis – positive sam-
ples were assayed by 16s rRNA and plasmid PCR and 
plotted on the plane of the corresponding Cq values. 
as PCR, holds a great promise to improve the 
management of infectious diseases at the pop-
ulation level in general. 
Here we suggested that targeting two loci 
could greatly improve C. trachomatis PCR 
diagnostics. We chose the 16s rRNA gene as 
the chromosomal target to supplement plas-
mid-born PCR. First, it is present in at least 
two copies (Fig. 1A) thus backing up the test 
if one of the copies picks up a mutation affect-
ing the primer — template interaction. Second, 
we wanted to reserve an option to detect non-
trachomatis Chlamydiaceae which would ex-
pand the use of 16s rRNA reaction in clinical 
and veterinary diagnostics. The 16s RNA gene 
offers enough conserved motives for designing 
primers to 16s rRNA sequence from a range 
of Chlamydia species (Fig. 2). At the same 
time, our Taqman probe (Fig. 1A) was suffi-
ciently restrictive narrowing down the range 
to C. trachomatis (Fig. 3 and data not shown).
The sensitivity and efficiency were similar 
for 16s rRNA and plasmid PCR, on both pure 
DNA (Fig. 3) and clinical samples (Fig. 6). 
The reactions were performed well in the 
multiplex format (Figs. 3 and 4). Thus the 
system does not appear to be affected by a 
reciprocal inhibiting effect of the reactions 
and exhaust of active components towards the 
end of PCR. Furthermore, the reactions were 
not perturbed by inhibitors potentially carried 
through the DNA isolation step (Fig. 5 and 
data not shown). Thus this PCR set could be 
combined with various DNA isolation kits and 
integrated into an existing laboratory work-
flow. Despite a high analytical sensitivity, the 
clinical sensitivity of a test based on the pro-
posed reactions remains to be determined. 
This should be done on a panel of reference 
clinical samples prepared under the same con-
ditions and deemed C. trachomatis-positive 
by a “golden standard” test.
For the quantification of C. trachomatis, 16s 
rRNA PCR appears more advantageous be-
cause the plasmid copy number is a variable 
parameter per se. Our results show that 16s 
rRNA, as a PCR target, is not worse than plas-
mid used traditionally. However, it would be 
premature to refuse from targeting the plasmid 
which is believed to be somehow associated 
with virulence [5]. It is plausible that the di-
agnostics of the future will be focused more 
on highly virulent stages and variants in order 
to avoid unnecessary therapeutic measures.
In rare samples, one of the two reactions 
failed (Fig. 6) which could be caused by (i) 
partial DNA degradation, (ii) sequence varia-
tion in primer target sites, (iii) infection erad-
ication. In general, since many aspects of 
C. trachomatis biology and pathogenesis still 
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remain unclear we suggest that a PCR diag-
nostic kit must be somewhat redundant. The 
use of two reactions, able to back-up each 
other on problematic samples, appears to be 
advantageous for the test’s reliability. 
Conclusions
The dual-target strategy for PCR detection of 
C. trachomatis presented here benefits from 
the simultaneous targeting the cryptic plasmid 
and 16s rRNA gene. Such a strategy offers a 
high sensitivity and reproducibility, performs 
well upon multiplexing, and ensures an effi-
cient C. trachomatis detection in samples 
where one of the targets is lost. Adoption of 
these reactions could be a launching point in 
the development of a quantitative kit for both 
in-house use and commercial production.
List of abbreviations
PCR, polymerase chain reaction; Cq – thresh-
old cycle in PCR amplification; geq/rxn, ge-
nome-equivalents per reaction; bp, base pairs. 
FAM,6-carboxyfluorescein; HEX, hexachlo-
rofluorescein; Cy5, cyanine-5; BHQ-1,2 and 
3, black-hole quencher-1,2 and 3, respectively.
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Двоцільова стратегія виявлення Chlamydia 
trachomatis за допомогою ПЛР у реальному часі
Я. О. Вітренко, О. М. Дерябін
Мішенню тестів діагностики C. trachomatis першого 
покоління є криптична плзмда. Нещодавно відкриті 
штами без цільового сегмента ДНК (т.зв. «Шведскі» 
варіанти) або повністю позбавлені плазміди не діа-
гностуються ПЛР. Мета. Запропоновано використову-
вати хромосомний ген в якості додаткової мішені, що 
дозволить підстрвахувати плазмідний ПЛР-тест і може 
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підвищити загальну ефективність діагностики. 
Методи. Мультиплексна система з двох ПЛР була 
складена для одночасної детекції криптичної плазміди 
і фрагмента гена 16s рРНК. Праймери на 16s рРНК 
можуть давати сигнал ПЛР при аналізі ряду видів 
Chlamydia. Додавання зонда типу Taqman (необхідно-
го для ПЛР в реальному часі) звужує спектр виявляв 
видів до C. trachomatis. У той же час, ПЛР з пла-зміди 
володіє специфічністю виключно до C. trachomatis. 
Результати. Чутливість ПЛР з плазміди і гена 16s 
рРНК досягала від 1 до 10 геном-еквівалентів на ре-
акцію, а ефективність – близько 100 %. Реакція в муль-
типлексі не зменшує аналітичну чутливість. Додавання 
до реакційної суміші ДНК клінічних зразків не впли-
вало на ПЛР з чистою ДНК C. trachomatis, що також 
демонструє надійність системи. Кінетику цих двох 
реакцій проаналізовано на 49 зразках ДНК з мазків, 
позитивних до C. trachomatis. Для 45 зразках показано 
хорошу кореляцію порогових циклів ампліфікації Cq – 
основного аналітичного параметра ПЛР у реальному 
часі. Висновки. Одночасна детекція хромосомної і 
плазмідной мішені в мультиплексній ПЛР забезпечує 
високу чутливість і має перевагу при аналізі зразків з 
втраченою плазмидою через деградацію ДНК або 
контрселекціі при терапії. Двоцільова стратегія ПЛР, 
може бути основою для ефективного внутрішньола-
бораторного або комерційного діагностичного тесту.
К л юч ов і  с л ов а: Chlamydia trachomatis, ПЛР у 
реальному часі, ген 16s рРНК, криптична плазміда
Двухцелевая стратегия выявления Chlamydia 
trachomatis с помощью ПЦР в реальном 
времени
Я. А. Витренко, О. Н. Дерябин
Мишенью тестов диагностики C. trachomatis первого 
поколения является криптическая плазмида. Недавно 
открытые штаммы без целевого сегмента ДНК(т.н. 
«шведские» варианты) или полностью лишенные плаз-
миды не диагностируются ПЦР. Цель. Предложено 
использовать хромосомный ген в качестве дополни-
тельной мишени, что позволит подстраховать плазмид-
ный ПЦР-тест  и может повысить общую эффектив-
ность диагностики. Методы. Мультиплексная система 
из двух ПЦР была составлена для одновременной де-
текции криптической плазмиды и фрагмента гена 16s 
рРНК. Праймери на 16s рРНК могут давать сигнал ПЦР 
при анализе ряда видов Chlamydia. Добавление зонда 
типа Taqman (необходимого для ПЦР в реальном вре-
мени) сужает спектр виявляемых видов до 
C. trachomatis. В то же время, ПЦР с плазмиды обла-
дает специфичностью исключительно к C. trachomatis. 
Результаты. Чувствительность ПЦР с плазмиды и гена 
16s рРНК  достигала от 1 до 10 геном-эквивалентов на 
реакцию, а эффективность – около 100 %. Реакция в 
мультиплексе не уменшала аналитическую чувстви-
тельность. Добавление к реакционнной смеси ДНК из 
клинических образцов не влияло на ПЦР с чистой ДНК 
C. trachomatis, что также демонстрирует надежность 
системы. Кинетика этих двух реакций проанализиро-
вана на 49 образцах ДНК из мазков, позитивных по 
C. trachomatis. В 45 образцах  реакции показали хоро-
шую корреляцию  порогових циклов амплификации 
Cq – основного аналитического параметра ПЦР в ре-
альном времени. Выводы. Одновременная детекция 
хромосомной и плазмидной мишеней в мультиплексной 
ПЦР обеспечивает высокую чувствительность и имеет 
преимущество при анализе образцов с утраченой плаз-
мидой из-за деградации ДНК или контрселекции при 
терапии. Двух-целевая стратегия ПЦР, может быть 
основой для эффективного внутрилабораторного или 
коммерческого диагностичного теста.
К л юч е в ы е  с л ов а: Chlamydia trachomatis, ПЦР у 
реальном  времени, ген 16s рРНК, криптичская плазмида
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